Dermatology · Research Phase
Myristoyl Pentapeptide-17
No lawful US pathway
01 · Overview
Myristoyl Pentapeptide-17 is a lipopeptide composed of a pentapeptide sequence conjugated to myristic acid, intended to improve penetration into the skin and hair follicle. It is marketed primarily for eyelash and eyebrow enhancement, with suppliers proposing that it stimulates keratin gene expression; this mechanism has not been confirmed in peer-reviewed studies.
A survey of 79 eyelash serums found that many rely on peptides and similar ingredients, while about 30 percent contained unregulated prostaglandin analogues, which can confound claims about any single ingredient (PMID 42269767).
02 · Research summary & key findings
No peer-reviewed laboratory or clinical studies of myristoyl pentapeptide-17 itself were found in PubMed. Reported increases in keratin synthesis and eyelash length or thickness come from supplier data and consumer studies that have not been independently published. No randomized, placebo-controlled trials have been published, and the peptide has no FDA approval for hair or eyelash growth.
03 · Regulatory status
Myristoyl Pentapeptide-17 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Myristoyl Pentapeptide-17 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 1 FDA-approved compound in Dermatology
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
Myristoyl Pentapeptide-17 is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Topical
References
- [1]Prostaglandin analogues in cosmetic products formulated for eyelash lengthening Ann Pharm Fr, 2026. PMID 42269767
Primary literature
- PubMed: "Myristoyl Pentapeptide-17"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Myristoyl Pentapeptide-17"
Registered interventional and observational studies, including status and phase.
- PubChem: "Myristoyl Pentapeptide-17"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Dermatology
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.